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The locus coeruleus (LC) is a brainstem nucleus distinguished by its supply of
noradrenaline throughout the central nervous system. Apart from modulating a range
of brain functions, such as arousal, cognition and the stress response, LC neuronal
excitability also corresponds to the activity of various peripheral systems, such as
pelvic viscera and the cardiovascular system. Neurochemically diverse inputs set the
tone for LC neuronal activity, which in turn modulates these adaptive physiological
and behavioral responses essential for survival. One such LC afferent system which
is poorly understood contains the neurohormone arginine-vasopressin (AVP). Here we
provide the first demonstration of the molecular and functional characteristics of the LC-
AVP system, by characterizing its receptor-specific modulation of identified LC neurons
and plasticity in response to stress. High resolution confocal microscopy revealed that
immunoreactivity for the AVP receptor 1b (V1b) was located on plasma membranes
of noradrenergic and non-noradrenergic LC neurons. In contrast, immunoreactivity for
the V1a receptor was exclusively located on LC noradrenergic neurons. No specific
signal, either at the mRNA or protein level, was detected for the V2 receptor in the LC.
Clusters immunoreactive for V1a-b were located in proximity to profiles immunoreactive
for GABAergic and glutamatergic synaptic marker proteins. AVP immunopositive
varicosities were also located adjacent to labeling for such synaptic markers. Whole-
cell patch clamp electrophysiology revealed that the pharmacological activation of V1b
receptors significantly increased the spontaneous activity of 45% (9/20) of recorded
noradrenergic neurons, with the remaining 55% (11/20) of cells exhibiting a significant
decrease in their basal firing patterns. Blockade of V1a and V1b receptors on their
own significantly altered LC neuronal excitability in a similar heterogeneous manner,
demonstrating that endogenous AVP sets the basal LC neuronal firing rates. Finally,
exposing animals to acute stress increased V1b, but not V1a receptor expression,
whilst decreasing AVP immunoreactivity. This study reveals the AVP-V1a-b system as
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a considerable component of the LC molecular architecture and regulator of LC activity.
Since AVP primarily functions as a regulator of homeostasis, the data suggest a novel
pathway by modulating the functioning of a brain region that is integral to mediating
adaptive responses.
Keywords: V1b, desmopressin, patch clamp, TASP 0390325, restraint stress
INTRODUCTION
The LC is a cluster of neurons located within the pons
distinguished from surrounding cell groups by their production
of the neurotransmitter noradrenaline (NA) (Dahlstroem and
Fuxe, 1964). Despite the compact size of this nucleus, the
principal neurons projects to almost all regions of the brain
and spinal cord, thereby serving as the primary source of
NA for the central nervous system (Schwarz and Luo, 2015).
The result is a LC-NA system that modulates some of the
most salient aspects of brain function such as arousal (Carter
et al., 2010), attention (Usher et al., 1999), and memory (Sara,
2015). These neural processes are combined to mediate a core
responsibility of the LC-NA system, that being the modulation
of adaptive responses to emotional and physiological stressors,
which is a process essential for survival in an ever dynamic
world (Valentino and Van Bockstaele, 2008). This is accomplished
by a highly dynamic excitability profile of LC neurons, which
results in the release of NA in precise spatiotemporal and brain-
state specific patterns. However, this contribution of the LC-NA
system to homeostasis extends beyond the CNS. Indeed, changes
in the activity of LC neurons have been associated with diverse
peripheral physiological states, such as intestinal contractility
(Lechner et al., 1997), changes in blood pressure (Curtis et al.,
1993), bladder contractility (Rickenbacher et al., 2008) and fluid
balance (Godino et al., 2005). Therefore, the factors that govern
LC neuronal excitability have the potential to impact on a vast
array of physiological processes both within the CNS and in a
number of major peripheral organs in health and disease.
The principal noradrenergic neurons of the LC have the
ability to fire action potentials spontaneously and independently
of synaptic inputs (Williams et al., 1991). However, their
firing frequency is strongly modulated by conventional
neurotransmitters (Cherubini et al., 1988; Singewald and
Philippu, 1998). Often co-expressed with GABAergic and
glutamatergic inputs are an assortment of neuropeptides which
either exert direct effects on LC neuronal excitability or modulate
the effects of the co-released neurotransmitters, and are thus
considered as neuromodulators (Zitnik, 2016). In contrast,
the role of another LC afferent system, distinguished by the
expression of the neurohormone AVP (Rood and De Vries, 2011)
is relatively poorly understood in terms of its contribution to LC
function.
The primary signature of AVP is that of a hormone that
acts on a range of physiological systems and is integral for
the maintenance of homeostasis. Primarily produced by the
hypothalamus, its multitude of functions include contributing to
the regulation of fluid balance (Bankir et al., 2017), blood pressure
(Lozic et al., 2018), thermoregulation (Daikoku et al., 2007),
stress, (Caldwell et al., 2017) as well as emotional and social
behavior (Wu et al., 2015). Although many of these functions
mirror those of the LC-NA system detailed above, evidence for
the cooperativity of these two homeostatic systems is rather
limited. This is due to the dearth of information on the molecular,
cellular and behavioral correlates of the AVP system within brain
pathways such as the LC.
In the mouse, AVP-immunoreactive axonal profiles have
been demonstrated in the region of the pons occupied by
the LC (Rood and De Vries, 2011). However, this single
labeling study failed to demonstrate the association of such
fibers with identified LC neurons or other LC neuromodulatory
afferent systems. This is important because the LC is composed
of morphologically diverse noradrenergic (Schwarz and Luo,
2015) and neurochemically diverse non-noradrenergic neurons
(Corteen et al., 2011). Furthermore, the specific receptors,
through which AVP might communicate with LC neurons
remain to be identified. Three AVP receptor subtypes have
been identified, namely AVP receptor 1a (V1a), 1b (V1b) and 2
(V2) (Thibonnier et al., 2002). Expression of the V1b receptor
at the mRNA level has been reported in the pons, but not
on identified LC neurons (Young et al., 2006). Evidence for
the association of AVP with LC is more developed at the
functional level. Recordings from neurons in the LC showed an
excitatory effect of AVP in gerbil (Olpe et al., 1987) and rat
(Berecek et al., 1987), whilst the injection of AVP into the LC
complex, not on identified LC neurons, of cats, altered posture
and vestibulospinal reflexes (Andre et al., 1992). However, such
effects on LC excitability have yet to be demonstrated in other
species, which is an important caveat given the demonstrated
species differences of the CNS AVP system (Tribollet et al.,
1998). Finally, although the contribution of AVP in the stress
response has been demonstrated in specific stress circuits
(Herman and Tasker, 2016), the activation of the LC AVP system,
during stress, has yet to be demonstrated. Here we provide
the first demonstration of the molecular and physiological
characteristics of AVP-receptor system within neurochemically
defined cellular networks of the mouse LC. We also show
that exposing mice to a single episode of stress dramatically
alters the expression of the LC AVP-receptor system, providing
evidence for the direct interaction of two major homeostatic
systems.
MATERIALS AND METHODS
All procedures involving animal experiments were approved by
the Animal Welfare and Ethical Review Body of the University
of Portsmouth and were performed by a personal license holder,
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under a Home Office-issued project license, in accordance with
the Animals (Scientific Procedures) Act, 1986 (United Kingdom)
and associated procedures.
Tissue Preparation for
Immunohistochemistry
Adult male C57BL/6J, as well as V1a and V1b receptor specific
gene-deleted (Tanoue et al., 2004; Koshimizu et al., 2006) mice,
2 months of age, were used to determine the native AVP
and AVP receptor subtype expression patterns, according to
a previously published protocol (Corteen et al., 2011). Briefly,
under anesthesia, animals were perfused transcardially with
0.9% saline solution for 2 min, followed by 12 min fixation
with a fixative consisting of 1% paraformaldehyde and 15% v/v
saturated picric acid in 0.1 M phosphate buffer (PB), pH 7.4.
The brains were post-fixed over night at room temperature in
the same perfusion fixative, sectioned with a vibratome and
stored in 0.1 M PB and 0.05% sodium azide until further
processing.
Immunohistochemistry
Non-specific binding of the secondary antibodies was minimized
by incubating the sections in TBS-Tx containing 20% normal
horse serum (S-2000, Vector Laboratories Inc.) for 2 h. Sections
were incubated in a cocktail of primary antibodies overnight
at 4◦C (Supplementary Table S1). The next day, the sections
were washed with TBS-Tx for 30 min after which they were
incubated at room temperature in a cocktail of an appropriate
mixture of secondary antibodies, conjugated with Alexa Fluor
488, indocarbocyanine (Cy3) and indocarbocyanine (Cy5), all
provided by Jackson ImmunoResearch, for 2 h. The sections
were washed in TBS-Tx for 30 min after which they were
mounted on glass slides, air dried and coverslipped using
Vectashield mounting medium (H-1000, Vector Laboratories
Inc.).
Image Acquisition
Sections were examined with a confocal laser-scanning
microscope (LSM710 or LSM 880; Zeiss, Oberkochen, Germany)
using a Plan Apochromatic 63 x DIC oil objective (NA 1.4, pixel
size 0.13 µm). Z-stacks were used for routine evaluation of the
labeling. All images presented represent a single optical section.
These images were acquired using sequential acquisition of the
different channels to avoid cross-talk between fluorophores,
with the pinholes adjusted to one Airy unit. Images were
processed with the software Zen 2009 Light Edition (Zeiss,
Oberkochen, Germany) and exported into Adobe Photoshop.
Only brightness and contrast were adjusted for the whole
frame, and no part of a frame was enhanced or modified in any
way.
Quantitative Real-Time Polymerase
Chain Reaction (qPCR) Detection of V2
mRNA
For complete methods, please see Supplementary Information.
Whole Cell Patch Clamp
Electrophysiology Recordings in Acute
Brain Slices of the LC
Recordings were performed in juvenile (postnatal day 25–
30) mice according to previously published protocols (Swinny
et al., 2010). Briefly, animals were rapidly decapitated and the
head placed in ice-cold oxygenated sucrose-cutting solution
containing (mM): sucrose (234), KCl (2.5), NaH2PO4 (1.25),
NaHCO3 (26), dextrose (10), MgSO4 (10), CaCl2 (0.5). The brain
was rapidly removed and blocked to isolate the brainstem region.
The trimmed brain was affixed to a Vibratome equipped with
a ceramic blade and submerged in ice cold oxygenated sucrose
cutting solution. Horizontal 200 µm slices of the brainstem
containing the LC were cut and placed in a holding vial
containing extracellular solution (ECS) containing (mM): NaCl
(126), KCl (2.95), NaH2PO4 (1.25), NaHCO3 (26), dextrose (10),
MgSO4 (2), CaCl2 (Sigma) for 1 h at 37◦ C, after which they were
kept at room temperature, and transferred one at a time to the
recording chamber.
A single slice was placed in the recording chamber and
continuously superfused with ECS at 1 ml/min at 32◦C.
LC neurons were visualized using an Olympus B50 upright
microscope fitted with a 40x water-immersion objective,
differential interference contrast and infrared filter. Recording
pipettes were fashioned from borosilicate glass capillary tubing
(1.2 mm o.d., 0.69 mm i.d.; Warner Instruments) using
a Narishige PC-10 micropipette puller. Pipettes were filled
with potassium gluconate intracellular solution containing: K-
Gluconate (70), KCl (70), HEPES (10), EGTA (10), MgCl2 (2),
CaCl2 (1), ATP (2) (Maguire et al., 2014) and 0.1 % biocytin (pH
7.3) to allow post-hoc identification of the cell.
A visualized cell was approached with the electrode, a G
seal established and the cell membrane ruptured to obtain
a whole-cell recording using a Multiclamp 700B amplifier
(Molecular Devices, United States). Series resistance was
monitored throughout the experiment. If the series resistance
of the electrode was unstable or exceeded four times the
electrode resistance, electrophysiological data from the cell were
discarded. The main criteria for accepting a recording were
an action potential amplitude of 65–70 mV, action potential
shape characteristic of an LC neuron and membrane potential
between −50 and −60 mV. If the cell retained a stable baseline
and resistance and did not depolarize over time, the cell was
retained for analysis. Signals were digitized by Digidata 1320-
series analog-to-digital converter and stored online using pClamp
9 software (Molecular Devices). Only one cell per slice was
recorded. The experimental protocol involved recording baseline
cell characteristics in current clamp, including FR (Hz), input
resistance [derived from the linear portion of a voltage–current
plot of hyperpolarizing current steps (M), resting membrane
potential (mV), membrane time constant (τ, ms), action potential
amplitude (mV) and duration (ms) and AHP amplitude (mV),
and AHP t1/2 duration (measured from the peak of the AHP
to half the amplitude of the AHP, in ms)]. After determining
baseline characteristics, the drugs were bath-applied for at
least 10 min after which the cell characteristics were measured
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again. Data were analyzed with Clampfit software (Molecular
Devices).
Following the recording, the pipette was gently retracted,
the slice removed from the recording chamber and submerged
in a vial containing 1% paraformaldehyde fixative overnight.
Following washing in TBS-Tx buffer, the sections were then
incubated with 20% normal horse serum for 1 h at room
temperature, followed by incubation with an antibody against
TH overnight at 4◦C. Following further washing with TBS-Tx,
the sections were incubated with a streptavidin conjugated to
Alexa Fluor 488 secondary antibody (1:1000) (Molecular Probes,
United States), in addition to an appropriate secondary antibody
to visualize TH, for 2 h at room temperature. Sections were then
imaged on a confocal microscope (Zeiss LSM 710) in order to
confirm that the recorded cell was located within the LC and was
immunopositive for TH.
Drugs
All chemicals for the recording solutions were obtained from
Sigma. Desmopressin, [d(CH2)51, Tyr(Me)2, Arg8]-Vasopressin
and TASP 0390325 were obtained from Tocris, United Kingdom,
and dissolved in ECS.
Acute Restraint Stress
A total of 10 (5 control and 5 stress) male mice, aged 2 months
were used in this part of the study. The animals were placed in
a rodent Plexiglas restrainer (Harvard Apparatus) for 60 min.
The animals were then returned to their home cages for a
further 60 min, after which they were killed, using the perfusion-
fixation protocol above and the tissue used for quantitative
immunohistochemistry.
Quantification of AVP and V1a-b
Receptor Immunoreactivity in the LC of
Tissue From Restraint Stress and
Control Mice
One hour after the cessation of the stress period, animals
were killed by perfusion fixation and the tissue prepared
for semi-quantitative analyses of AVP and V1a-b receptor
immunoreactivity as above. The quantitative method has been
previously described (Gunn et al., 2013) and is detailed in
Supplementary Method.
Statistical Analysis
All quantitative data are presented as the mean± SEM. Statistical
differences between means were assessed using GraphPad Prism
software, with the names of statistical tests used indicated in
the Results section. A p-value less than 0.05 was considered
statistically significant.
RESULTS
The overall aims of the project were to identify the AVP receptor
subtypes expressed by LC neurons, the location of these receptors
within the cellular networks of the LC, their contribution to
LC neuronal excitability and whether they are engaged by acute
stress.
Verification of the Specificity of AVP
Receptor Immunoreactivity
A key determinant of a direct AVP influence on LC function
would be the presence, and subtype, of AVP receptors in this
brain region. Since there is evidence for the expression of all
AVP receptor subtypes in the brain, from the outset, we sought
to identify whether specific AVP receptor subtypes are expressed
on identified LC neurons. In tissue from wild type (WT) mice,
V1a receptor immunoreactivity presented as individual clusters
enriched on the somata and dendrites of LC noradrenergic
neurons, identified by immunoreactivity for the NA synthesizing
enzyme tyrosine hydroxylase (TH) (Figure 1A1). In tissue from
V1a receptor knockout mice, no such specific V1a receptor
labeling pattern was detectable, with most of the signal enriched
in nuclei or scattered diffusely showing no clear association with
any cellular profiles, thus confirming the specificity of the V1a
antibody used (Figure 1A2). In WT tissue, immunoreactivity
for the V1b receptor also presented as clustered signal on
somatodendritic compartments of LC noradrenergic neurons.
However, in contrast to V1a, signal for V1b appeared more
widespread and was likely contained on LC non-noradrenergic
neurons as well (Figure 1B1). This labeling pattern was absent
in tissue from V1b receptor knockout mice, thus confirming
the specificity of the V1b antibody used (Figure 1B2). No
specific labeling for the V2 receptor was detectable in the LC
(Figures 1C1,C2). We further verified the lack of V2 receptor
expression in the LC, at the mRNA level, by performing
quantitative RT-PCR on tissue from the LC and another tissue
site known to express this receptor, namely the kidney (N = 5
mice). Whilst robust V2 receptor mRNA expression was detected
in kidney samples, only negligible amounts were evident in
LC samples (Figure 1C3). We therefore conclude that V1a-b
receptors are the major subtypes expressed in the mouse LC.
The V1b Receptor Is Expressed by
Noradrenergic and Non-noradrenergic
Neurons of the LC in Close Proximity to
Excitatory and Inhibitory Synapses
We first examined the expression profile of the V1b receptor as
it appeared to be more widely distributed throughout the LC,
compared to the V1a receptor, and is possibly associated with
both noradrenergic and non-noradrenergic profiles (compare
Figures 1A1,B1). We have shown that the LC is composed of not
only noradrenergic neurons, but also a range of neurochemically
diverse non-noradrenergic neurons (Figure 2A1) (Corteen et al.,
2011). In order to gain an integrative perspective of the role
of the AVP system within the cellular networks of the LC,
we sought to characterize the location of the V1b receptor
throughout LC circuitry. High resolution imaging revealed
that V1b receptor immunoreactivity was enriched on the
plasma membranes of LC neurons with significantly lower
levels of signal located in their cytoplasmic compartments,
characteristic of a metabotropic receptor (Figure 2A2). Signal
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FIGURE 1 | Confirmation of the specificity of the V1a and V1b receptor antibody labeling in the LC. (A1) Shows immunoreactivity for tyrosine hydroxylase (TH) (blue)
and the V1a receptor (yellow) in tissue from WT mouse. TH is the enzyme essential for noradrenaline synthesis and thus identifies the principal neurons of the LC.
V1a signal is exclusively associated with TH-immunopositive profiles. (A2) Shows, immunoreactivity for TH (blue) and V1a receptor (yellow) in tissue from a V1a
knock out mouse. Only weak, non-specific nuclear signal is evident confirming the specificity of the V1a antibody labeling pattern. (B1) Shows immunoreactivity for
tyrosine hydroxylase (TH) (blue) and the V1b receptor (yellow) in tissue from WT mouse. V1b signal is associated with TH-immunopositive cells as well as areas not
containing TH-immunopositive profiles. (B2) Shows, immunoreactivity for TH (blue) and V1b receptor (yellow) in tissue from a V1b knock out mouse. Only weak,
non-specific signal is evident confirming the specificity of the V1b antibody labeling pattern. (C1) Shows TH immunoreactivity. (C2) Shows, in the corresponding field
of view, labeling for an antibody against the V2 receptor. No specific signal was detectable. (C3) Shows the expression of mRNA for the V2 receptor in tissue from
the LC and the kidney which is known to express this receptor subtype. Whilst robust mRNA expression was detected in kidney, negligible expression was evident in
LC samples. N = 5 animals, with the bars representing the means and the error bars, the SEM. Scale bars (A,B), 10 µm; (C) 20 µm.
was also located on the somata of non-noradrenergic LC
neurons (Figure 2A3), identified by immunoreactivity for
the pan-neuronal marker protein HuC (Okano and Darnell,
1997) (Figures 2A3,A4). In addition to somatic labeling, V1b
receptor was also located on dendritic profiles, delineated by
immunoreactivity for microtubule associated protein 2 (MAP2)
(Figure 2B).
This clustered distribution of V1b receptor immunoreactivity
across the surfaces of LC neurons overlapped with the locations
of previously demonstrated GABAergic (Corteen et al., 2011)
and glutamatergic (Seifi et al., 2014) inputs. Furthermore,
since AVP has been shown to modulate synaptic transmission
(Ostergaard et al., 2014), we investigated the proximity
of V1b receptor-immunoreactive clusters to excitatory and
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FIGURE 2 | V1b receptor is expressed on noradrenergic and non-noradrenergic LC neurons in close proximity to glutamatergic and GABAergic synapses. (A1)
Shows immunoreactivity for TH (blue), a marker of noradrenergic neurons and HuC (cyan), a pan-neuronal marker. Thus, in this brain region, HuC identifies
noradrenergic (arrowhead) and non-noradrenergic (arrow) neurons of the LC. (A2) Shows, in the same field of view, immunoreactivity for TH (blue) and V1b receptor
(magenta), confirming its expression in LC noradrenergic neurons (arrowhead). V1b receptor signal presents as individual clusters concentrated on somatodendritic
plasma membranes, typifying the expression pattern of a metabotropic receptor. (A3) shows, in the same field of view, immunoreactivity for V1b receptor (magenta)
and HuC (cyan), confirming V1b receptor expression in LC non-noradrenergic neurons as well (arrow). (A4) Is an overlay and magnified view of the boxed area in
(A1–A3). (B1) Shows immunoreactivity for TH (blue), and microtubule associated protein 2 (MAP2) (cyan), a protein enriched in dendrites. (B2) shows, in the same
field of view, immunoreactivity for TH (blue) and V1b receptor (magenta), which confirms V1b expression on dendritic compartments. (B3) Shows, in the same field of
view, the association of immunoreactivity for V1b (magenta) with MAP2 (cyan), confirming V1b expression in dendritic compartments as well. (B4) Is an overlay and
magnified view of the boxed area in (B1–B3). (C1) Shows immunoreactivity for TH (blue), and vesicular glutamate transporter 2 (VGLUT2) (cyan), a protein enriched
in glutamatergic axon terminals and used here to identify presynaptic domains of excitatory synapses. (C2) Shows, in the same field of view, immunoreactivity for TH
(blue) and V1b receptor (magenta). (C3) Shows, in the same field of view, the association of immunoreactivity for V1b receptor (magenta) with VGLUT2 (cyan). The
(Continued)
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FIGURE 2 | Continued
close association suggests that the V1b receptor in LC neurons is expressed in close proximity to excitatory synapses. (C4) Is an overlay and magnified view of the
boxed area in (C1–C3). (D1) Shows immunoreactivity for TH (blue), and vesicular GABA transporter (VGAT) (cyan), a protein enriched in GABAergic and glycinergic
axon terminals and used here to identify presynaptic domains of inhibitory synapses. (D2) Shows, in the same field of view, immunoreactivity for TH (blue) and V1b
(magenta). (D3) Shows, in the same field of view, the association of immunoreactivity for V1b (magenta) with VGAT (cyan). The close association suggests that V1b
on LC neurons is expressed in close proximity to inhibitory synapses as well. (D4) Is an overlay and magnified view of the boxed area in (D1–D3). (E1) Shows
immunoreactivity for TH (blue), and gephyrin (cyan), a protein that anchors GABAA and glycine receptors in inhibitory synapses and used here to identify
postsynaptic domains of inhibitory synapses. (E2) Shows, in the same field of view, immunoreactivity for TH (blue) and V1b (magenta). (E3) Shows, in the same field
of view, the association of immunoreactivity for V1b (magenta) with gephyrin (cyan). There is sparse colocalization of clusters immunoreactive for V1b and gephyrin
suggesting a limited incorporation of V1b in inhibitory postsynaptic domains, with this receptors located most likely on perisynaptic compartments. (E4) Is an overlay
and magnified view of the boxed area in (E1–E3). Scale bars (A1–A3) 20 µm; (A4,B–D1–D3) 10 µm; (B–D4) 5 µm.
inhibitory synaptic marker proteins. Clusters immunoreactive
for the vesicular glutamate transporter 2 (VGLUT2) contacted
the somatic and dendritic surfaces of TH-immunopositive
neurons, thereby identifying glutamate release sites on these
neurons (Figure 2C1). Evaluation of immunoreactivity for
VGLUT2 alongside the V1b receptor revealed a proportion
of closely apposed clusters for either molecule, suggesting
that a proportion of V1b receptors function in proximity to
glutamatergic synapses (Figures 2C2,C3). However, there was
also a notable proportion of V1b receptor-immunoreactive
clusters located on cell surfaces which were devoid of VGLUT2-
immunoreactive contacts (Figures 2C3,C4). Immunoreactivity
for the vesicular GABA transporter (VGAT) was used to
identify the domains of inhibitory synaptic inputs. VGAT
signal was widely distributed across the somatodendritic
surfaces of LC neurons (Figure 2D1). In a similar manner,
a proportion of V1b receptor immunoreactive clusters were
adjacent to clusters immunoreactive for VGAT, although some,
particularly those on somatic membranes were not associated
with VGAT signal (Figures 2D2–D4). Since VGAT and
VGLUT2 identify presynaptic compartments, we used gephyrin,
a protein that anchors GABAA and glycine receptors in the
postsynaptic compartments of inhibitory synapses, in order to
assess any enrichment of the V1b receptor in postsynaptic
junctions. A relatively sparse association of V1b and gephyrin
immunoreactivity was evident (Figure 2E). However, at the
light microscopical level, it is not possible to determine the
precise location of these receptors, or other proteins, in proximity
to presynaptic, postsynaptic, perisynaptic or extrasynaptic
compartments. Therefore, further ultrastructural analyses, using
immunohistochemistry and transmission electron microscopy
is required to unequivocally determine the location of these
receptors in proximity to synaptic junctions.
V1b Receptor Activation Has Contrasting
Effects on the Spontaneous Firing of LC
Noradrenergic Neurons
Given the close proximity of V1b receptor signal to synaptic
inputs, we next investigated whether the pharmacological
activation of V1b receptors alters the spontaneous excitability
of identified LC neurons by using whole cell patch clamp
electrophysiology in acute brain slices containing the LC. In light
of the LC consisting of noradrenergic and non-noradrenergic
neurons, all cells were loaded with biocytin during the recording
in order to verify their location within the LC and their
neurochemical identity. Only cells positively identified as TH-
immunopositive and located within the LC core, were included
in the analyses (Figure 3A). The spontaneous firing rates
(FR) of the recorded neurons were indistinguishable from
previously published studies, with the mean ± SEM FR of
1.7 ± 0.1 Hz, ranging from 0.2 Hz to 3.2 Hz, N = 50
cells from 15 animals (Supplementary Tables S2–S7). The
associated membrane properties of the neurons are also detailed
in Supplementary Tables S2–S7. It was noticeable from the
outset that V1b receptor activation, by applying the synthetic
vasopressin analog desmopressin (200 µM), which acts as an
agonist at V1b and V2 receptors, either increased, or decreased
the spontaneous FRs of LC neurons. We therefore categorized the
recorded neurons into groups which exhibited either an increase
or decease in their activity in response to the drug. Desmopressin
significantly increased the FR of LC neurons from 1.7 ± 0.3 Hz
to 2.9 ± 0.3 Hz, p = 0.01, paired Student’s t-test; N = 9 cells
(Figures 3B1,B2). Desmopressin also significantly decreased the
afterhyperpolarization (AHP) time constant from 65 ± 6 ms
to 53 ± 5 ms, p = 0.005, paired Student’s t-test; N = 8 cells
(Figure 3B3). There were no significant differences in any other
cell characteristics following the application of desmopressin
(Supplementary Table S2). In a separate cohort of cells, recorded
under identical conditions, desmopressin significantly decreased
the FR of LC neurons from 1.4 ± 0.3 Hz to 0.9 ± 0.2 Hz,
p = 0.02, paired Student’s t-test; N = 11 cells (Figures 3C1,C2).
In this group of cells, desmopressin also significantly decreased
the action potential amplitude (69 ± 1.8 mV to 45.5 ± 9.3 mv,
p = 0.02, paired Student’s t-test; N = 11 cells, Figure 3C1) and
increased the AHP time constant from 67± 8 ms to 167± 44 ms,
p = 0.03, paired Student’s t-test; N = 11 cells (Figure 3C3). In this
group of cells, there were no significant differences in any other
cell characteristics following the application of desmopressin
(Supplementary Table S2). Thus, the activation of V1b receptors
bi-directionally modulates the excitability of LC neurons.
We then explored whether locally released AVP contributes
to the basal FR of LC neurons by recording the FR of LC
neurons following the blockade of V1b receptors in the presence
of the V1b receptor selective antagonist TASP 0390325 (Iijima
et al., 2014). In a similar trend to desmopressin, TASP 0390325,
20 nM, either increased (2.2 ± 0.1 Hz to 3.2 ± 0.3 Hz, p = 0.01,
paired Student’s t-test, N = 8 cells, Figures 3D1,D2) or decreased
(1.7 ± 0.2 Hz to 1.3 ± 0.3 Hz, p = 0.03, paired Student’s t-test,
N = 6 cells, Figures 3E1,E2) the spontaneous FR of neurons.
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FIGURE 3 | V1b receptor modulation directly alters LC noradrenergic neuronal activity. (A) Post hoc microscopical confirmation of the molecular identity and location
of recorded neurons. (A1) Shows immunoreactivity for biocytin which was originally contained within the intracellular solution used for recording the neuron in the
whole-cell configuration. Note that immunoreactivity is located exclusively within the single neuron (arrow). (A2) Shows immunoreactivity for TH within the same filed
of view as (A1), confirming that the recording was from the LC, with the arrow highlighting the recorded cell. (A3) Is an overlay and magnified view the cell in (A1,A2)
confirming that the recorded cell is TH immunopositive and thus a noradrenergic LC neuron. (B1) Representative traces of the spontaneous firing pattern of an LC
neuron before and after the application of the V1b receptor agonist desmopressin 200 µM, from a cohort of neurons that responded with a significant increase in the
frequency of spontaneous action potentials. (B2) Quantification of the spontaneous firing rates (Hz) of LC neurons before and after the application of desmopressin
(DES). (B3) Quantification of the after hyperpolarization time constant (msec) of LC neurons before and after the application of desmopressin. (C1) representative
traces of the spontaneous firing pattern of an LC neurons before and after the application of the V1b receptor agonist desmopressin 200 µM, from a cohort of
neurons that responded with a significant decrease in the frequency of spontaneous action potentials. (C2) Quantification of the spontaneous firing rates (Hz) of LC
neurons before and after the application of desmopressin. (C3) Quantification of the after hyperpolarization time constant (msec) of LC neurons before and after the
application of desmopressin. (D1) Representative traces of the spontaneous firing pattern of an LC neuron before and after the application of the V1b receptor
antagonist TASP 0390325, 20 nM, from a cohort of neurons that responded with a significant increase in the frequency of spontaneous action potentials. (D2)
Quantification of the spontaneous firing rates (Hz) of LC neurons before and after the application of TASP 039325. (D3) Quantification of the afterhyperpolarization
time constant (msec) of LC neurons before and after the application of TASP 039325. (E1) Representative traces of the spontaneous firing pattern of an LC neuron
before and after the application of the V1b antagonist TASP 0390325, 20 nM, from a cohort of neurons that responded with a significant decrease in the frequency
of spontaneous action potentials. (E2) Quantification of the spontaneous firing rates (Hz) of LC neurons before and after the application of TASP 039325. (E3)
Quantification of the afterhyperpolarization time constant (msec) of LC neurons before and after the application of TASP 039325. For graphs in (B–E), the dots
represent the values for individual cells, the long red bars represents the mean for all cells within that group, and the short red bars represent the SEM. ∗p < 0.05,
paired Student’s t-test. Scale bars (A1,A2) 50 µm; (A3) 20 µm; (B1,C1,D1,E1) horizontal bar 1 s, vertical bar 10 mV.
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However, in contrast to desmopressin, TASP 0390325 did not
significantly alter the AHP time constant either in those cells
that showed an increased (65 ± 6 ms to 58 ± 4, p = 0.3442,
paired Student’s t-test; N = 8 cells, Figure 3D3) or decreased FR
(78 ± 13 ms to 72 ± 10 ms, p = 0.3442, paired Student’s t-test;
N = 6 cells, Figure 3E3). This provides evidence that endogenous
AVP and V1b receptor activation contributes to the basal level of
LC activity.
The V1a Receptor Is Expressed
Exclusively by Noradrenergic Neurons of
the LC
In contrast to the V1b receptor, V1a receptor immunoreactivity
was restricted to LC TH-immunopositive neurons, both
on somatic (Figure 4A) and dendritic (Figure 4B)
compartments, with TH immunonegative cell, identified by
HUC immunoreactivity devoid of any TH signal. In common
with the V1b receptor, clusters immunoreactive for V1a were also
located, on occasion, in proximity to puncta immunoreactive for
VGLUT2 (Figure 4C) and VGAT (Figure 4D).
V1a Receptor Blockade Has Contrasting
Effects on the Spontaneous Firing of LC
Noradrenergic Neurons
In a similar trend to the V1b receptor, blockade of the V1a
receptor with the antagonist [(d(CH2)51, Tyr(Me)2, Arg8)-
Vasopressin, 30 nM] (n = 16) also had contrasting effects on LC
FR. Indeed, 62% of the cells responded with an increase in their
FR (1.6 ± 0.2 Hz to 2.1 ± 0.3 Hz; p = 0.0016, paired Student’s
t-test, N = 8 cells, Figures 5A1,A2). However, in contrast to
the effects of the V1b antagonist, V1a blockade did result in a
significant decrease in AHP of the neurons (73± 9 ms to 60± 6,
p = 0.0185, paired Student’s t-test; N = 8 cells, Figure 5A3).
The remaining cells responded with a decrease in their FR
(2.0 ± 0.2 Hz to 1.4 ± 0.2 Hz; p = 0.0172, paired Student’s
t-test, N = 6 cells, Figures 5B1,B2). However, in these subset
of cells, there were no significant differences between the AHP
(61 ± 4 ms to 69 ± 10, p = 0.5117, paired Student’s t-test; N = 6
cells, Figure 5B3). This provides evidence that endogenous AVP
and V1a-b receptors contributes to the basal level of LC activity.
These data are summarized in Supplementary Tables S6, S7.
AVP-Containing Axons Contact
Noradrenergic and Non-noradrenergic
Neurons of the LC in Close Proximity to
Excitatory and Inhibitory Synapses
The V1a-b antagonist data above provide evidence that AVP
within the LC regulates the basal levels of neuronal activity.
This could identify a novel pathway that modulates behavioral
states associated with changes in both AVP production (Caldwell
et al., 2017), and LC neuronal activity (McCall et al., 2015),
such as psychosocial stress. For native AVP to exert a significant
control over LC-mediated brain functions, there would need
to be a considerable distribution of afferents containing this
neurohormone throughout the LC. Since previous reports
provide only low resolution images of AVP-immunoreactive
profiles within the region of the pons occupied by the LC
(Rood and De Vries, 2011), we undertook a high resolution
characterization of the native association of AVP-containing
profiles with identified LC neurons.
The specificity of the LC AVP labeling pattern was replicated
using two different AVP antibodies, and the paraventricular
nucleus (PVN) as a positive control brain region. Both
antibodies provided a pattern of immunoreactivity within the
PVN that was consistent with previously published reports
(Zhang and Hernandez, 2013) (Figure 6A). However, antibody
AC39363 produced a superior signal to noise ratio and was
therefore used for remainder of the study. Within the LC, AVP
immunoreactivity presented as a mixture of varicose plexuses
and individual clusters contacting LC neurons (Figures 6B,C).
Importantly, AVP immunoreactivity was distributed through the
entire extent of the LC, both within the nuclear core, as well as in
the pericoeruleur dendritic region (Figures 6B,C). We found no
evidence of specific AVP-immunoreactive neurons within the LC.
Upon close inspection, AVP immunoreactive varicosities
contacted both noradrenergic (Figures 7A1,A2) and non-
noradrenergic (Figures 7A3,A4) neurons of the LC. In
addition to this association with somatic compartments, AVP-
immunoreactive varicosities also contacted dendritic profiles
(Figure 7B), thus closely mirroring the distribution of V1a-b
receptors in this brain region. Unfortunately, both antibodies for
AVP and V1a-b receptors were raised in the same species, thus
precluding co-association studies. Nevertheless, we evaluated
the association of AVP immunoreactivity alongside the synaptic
marker proteins used for the V1a-b receptors receptor analyses,
in an attempt to extrapolate the degree of coherence for their
respective locations within these neurons. AVP-immunoreactive
profiles were strongly associated with VGLUT2 immunopositive
clusters (Figure 7C). However, AVP immunoreactivity showed
relatively less association with the inhibitory synaptic markers
proteins VGAT (Figure 7D) and gephyrin (Figure 7E). Thus,
AVP-immunoreactive axonal profiles are distributed throughout
the LC, suggesting a pool of this neurohormone that has the
potential to impact on LC neurons.
AVP-Immunoreactive Profiles Show
Sparse Association With Other LC
Neuromodulatory Afferent Pathways
It is currently unclear whether LC AVP-immunopositive fibers
contain other neuropeptides known to provide modulatory
input to this nucleus. We therefore assessed the degree
of colocalization between AVP-immunoreactive profiles and
varicosities immunopositive for the predominant neuropeptides
that have been shown to directly contact LC neurons and
alter their excitability, namely substance P (Guyenet and
Aghajanian, 1979; Pickel et al., 1979), enkephalin (Valentino
and Wehby, 1989; Van Bockstaele et al., 1995), orexin A
(Hagan et al., 1999; Horvath et al., 1999), and CRH (Valentino
et al., 1983; Van Bockstaele et al., 1996). Only subsets of
AVP-immunoreactive varicosities showed colocalization with
substance P-immunopositive puncta with the vast majority
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FIGURE 4 | Within the LC, the V1a receptor is expressed exclusively on noradrenergic neurons. (A1) Shows immunoreactivity for TH (blue) and HuC (cyan), with the
arrowheads highlighting non-noradrenergic neurons of the LC. (A2) Shows, in the same field of view, immunoreactivity for TH (blue) and V1a receptor (magenta),
confirming that its expression, within the LC, is restricted to noradrenergic neurons and (A3) is not located on non-noradrenergic neurons (arrowheads). (A4) Is an
overlay of (A1–A3). (B1) Shows immunoreactivity for TH (blue) and MAP2 (cyan) with the arrowhead highlighting a non-noradrenergic dendritic profile. (B2) shows, in
the same field of view, immunoreactivity for TH (blue) and V1a receptor (magenta), which confirms V1a expression on noradrenergic profiles and (B3) not on
non-noradrenergic profiles (arrowhead). (B4) Is an overlay of (B1–B3). (C) and (D) show the association of V1a immunoreactivity with VGLUT2 and VGAT labeling
respectively. Scale bars (A) 15 µm; (B–D) 10 µm.
appearing mutually exclusive (Figure 8A). There was no
detectable association between profiles immunoreactive for AVP
and enkephalin (Figure 8B), orexin A (Figure 8C), and CRH
(Figure 8D). An obvious caveat is that whilst AVP and these
other neuropeptides may be contained in the same axons, they
may not necessarily be located within the same regions of the
axon, thus precluding the confirmation of their co-expression
using colocalization analysis. Nevertheless, the data suggests
that AVP-containing afferents could represent a distinct axonal
pathway within the LC.
Acute Stress Engages the LC-AVP
System
A key contribution of the LC to brain function is the modulation
of behavior that allows for adaptation to psychosocial stress
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FIGURE 5 | V1a receptor modulation directly alters LC noradrenergic neuronal activity. (A1) Representative traces of the spontaneous firing patterns of an LC neuron
before and after the application of the V1a receptor antagonist [d(CH2)51, Tyr(Me)2, Arg8]-Vasopressin, 30 nM, from a cohort of neurons that responded with a
significant increase in the frequency of spontaneous action potentials. (A2) Quantification of the spontaneous firing rates (Hz) of LC neurons before and after the
application of the V1a receptor antagonist. (A3) Quantification of the afterhyperpolarization time constant (msec) of LC neurons before and after the application of the
V1a receptor antagonist. (B1) Representative traces of the spontaneous firing patterns of an LC neuron before and after the application of the V1a receptor
antagonist, from a cohort of neurons that responded with a significant decrease in the frequency of spontaneous action potentials. (B2) Quantification of the
spontaneous firing rates (Hz) of LC neurons before and after the application of the V1a receptor antagonist. (B3) Quantification of the afterhyperpolarization time
constant (msec) of LC neurons before and after the application of the V1a receptor antagonist. In the graphs, the dots represent the values for individual cells, the
long red bars represents the mean for all cells within that group, and the short red bars represent the SEM. ∗p < 0.05, paired Student’s t-test. Scale bars (A1,B1)
horizontal bar 1 s, vertical bar 10 mV.
(Valentino and Van Bockstaele, 2008). The neurohormone
corticotrophin releasing hormone (CRH) (Vale et al., 1981),
released from afferents originating from the amygdala (Van
Bockstaele et al., 2001), is the primary driver of the increased
activity of LC neurons that underlies this behavioral response
(Valentino et al., 1983; McCall et al., 2015). However, AVP is
also released, together with CRH, from the hypothalamus, as
part of the hypothalamic-pituitary-adrenal stress axis (O’connor
et al., 2000). Given the evidence that both AVP and CRH are
contained in afferents that target LC neurons and both have
now been shown to alter LC neuronal activity (this study for
AVP), we explored whether acute stress engages the LC-AVP
system following exposure to 1 h of restraint stress (Buynitsky
and Mostofsky, 2009).
The intensity and pattern of V1a receptor immunoreactivity
was indistinguishable in tissue from control and stress animals,
processed and imaged under identical conditions (Figure 9A).
Semi-quantitative analysis of the density (number of clusters
per area) of V1a receptor immunoreactive clusters revealed
no significant differences between control and stress subjects
(control: 5782 ± 409 clusters per 100 µm2 versus stress:
4844 ± 753 clusters per 100 µm2; p = 0.3054, unpaired Student’s
t-test, N = 5 animals).
In contrast, we detected a significant increase in the number
of V1b receptor immunoreactive clusters, especially within
cytoplasmic domains (Figure 9B). Semi-quantitative analysis
of the density (number of clusters per area) of V1b receptor
immunoreactive clusters revealed a significant increase in tissue
in stress subjects (control: 945± 173 clusters per 100 µm2 versus
stress: 4462 ± 307 clusters per 100 µm2; p < 0.0001 unpaired
Student’s t-test, N = 5 animals). This dramatic stress-induced
alteration in V1b receptor immunoreactivity was accompanied
by a change in the AVP immunoreactivity pattern. In tissue
from control animals, AVP immunoreactivity presented as a
mixture of varicose plexuses and individual clusters throughout
the LC (Figures 9C1–C3). However, in tissue from stress
subjects, processed and imaged under conditions identical to
control, there was a noticeable decrease in the intensity of AVP
immunoreactivity within the LC, with a relative lack of varicose
plexuses (Figures 9C4–C6). Because AVP signal presented as
a mixture of varicose plexuses and individual clusters, we
performed the semi-quantitative analysis using fluorescence
intensity which will incorporate both patterns of signal. Stress
induced a moderate, though statistically significant decrease in
the AVP fluorescence intensity [control: 35 ± 2 arbitrary units
(AU) versus stress: 27 ± 2 AU, p = 0.04, unpaired Student’s
t-test, N = 5 animals]. This suggests that stress engages the LC
AVP-receptor system.
DISCUSSION
The current study provides the first demonstration of the
association of AVP-immunopositive axons with identified
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FIGURE 6 | Confirmation of AVP immunoreactivity, in the hypothalamus and LC. (A1,A2) Show the comparative immunoreactivity patterns of two different AVP
antibodies, in the paraventricular nucleus of the hypothalamus. AC39363 is the antibody obtained from Abcam and IS20069 is the antibody obtained from
ImmunoStar, with further details provided in Supplementary Table S1. Both antibodies replicate the characteristic pattern of AVP expression expected in this brain
region (Zhang and Hernandez, 2013). (B,C) Show the comparative labeling patterns of these AVP antibodies in the LC, when used under conditions identical to
those for hypothalamic tissue. (B3,C3) Shows that within the LC, AVP immunoreactivity presented as a combination of varicose plexuses and individual clusters
contacting somatodendritic surfaces. Scale bars (A) 100 µm; (B1,B2,C1,C2) 50 µm; (B3,C3) 10 µm. III, third ventricle.
noradrenergic and non-noradrenergic neurons of the LC.
These AVP-containing axons showed only a sparse association
with another neuropeptide afferent system within this brain
region, namely substance P. This suggests that AVP input
to the LC represents a pathway distinct to the myriad
of neuropeptide systems that modulate information transfer
to this nucleus. Furthermore, we identify the specific AVP
receptors within the LC, by localizing the V1a and V1b
receptors to the somatodendritic surfaces of these different
LC cell types. The modulation of both receptor subtypes
induced heterogeneity in the excitability of LC noradrenergic
neurons, manifesting as either an increase or decrease in
their spontaneous FR. Given the strong association between
LC FR and the level of NA release, this suggests that this
individual neurohormone is capable of both increasing and
diminishing CNS NA levels. Finally, we provide evidence
that exposing mice to a form of stress which generally
induces adaptive behavioral and physiological responses, results
in molecular plasticity in the AVP-receptor system. This
potentially identifies AVP as an integral component of the
molecular machinery utilized in LC-mediated homeostatic
responses.
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FIGURE 7 | Native AVP-containing axonal profiles contact both noradrenergic and non-noradrenergic LC neurons in close proximity to glutamatergic and GABAergic
synapses. (A1) Shows immunoreactivity for TH (blue) and HuC (yellow), indicating the distribution of noradrenergic and non-noradrenergic neurons (double arrow)
(A2) shows, in the same field of view, immunoreactivity for TH (blue) and AVP (magenta) immunoreactive profiles contacting LC noradrenergic neurons (arrowhead).
(A3) Shows, in the same field of view, immunoreactivity for AVP (magenta) and HuC (yellow), confirming the association of AVP with LC non-noradrenergic neurons
as well (arrows). (A4) Is an overlay of (A1–A3). (B1) Shows immunoreactivity for TH (blue), and MAP2 (cyan). (B2) Shows, in the same field of view, immunoreactivity
for TH (blue) and AVP (magenta). (B3) Shows, in the same field of view, the association of immunoreactivity for AVP (magenta) with MAP2 (cyan). Note the close
apposition of the AVP-immunopositive varicosity with the dendritic profile (arrowheads). (B4) Is an overlay of (B1–B3). (C1) Shows immunoreactivity for TH (blue),
and VGLUT2 (cyan). (C2) Shows, in the same field of view, immunoreactivity for TH (blue) and AVP (magenta). (C3) Shows, in the same field of view, the strong
association of immunoreactivity for AVP (magenta) with VGLUT2 (cyan) (arrowheads). (C4) Is an overlay of (C1–C3). (D1) Shows immunoreactivity for TH (blue), and
VGAT (cyan. (D2) Shows, in the same field of view, immunoreactivity for TH (blue) and AVP (magenta). (D3) Shows, in the same field of view, the association of
immunoreactivity for AVP (magenta) with a few VGAT-immunopositive clusters (cyan). (D4) Is an overlay of (D1–D3). (E1) Shows immunoreactivity for TH (blue), and
gephyrin (cyan). (E2) Shows, in the same field of view, immunoreactivity for TH (blue) and AVP (magenta). (E3) Shows, in the same field of view, the relatively sparse
association of immunoreactivity for AVP (magenta) with gephyrin (cyan). (E4) Is an overlay of (E1–E3). Scale bars (A) 15 µm; (B–E) 10 µm.
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FIGURE 8 | Association of AVP with LC neuromodulatory afferent systems. (A1) Immunoreactivity for TH (blue) and substance P (Sub P) (cyan). In the same field of
view, (A2) immunoreactivity of TH with AVP. (A3) Is an overlay of (A1,A2) showing isolated instances of colocalization of immunoreactivity for substance P and AVP
(arrowheads). Immunoreactivity for TH with (B1) enkephalin (ENK), (C1) orexin A (ORX) and (D1) CRH, with arrowheads highlighting a subset of varicosities in
(B1,D1). (B2,C2,D2) Show immunoreactivity of TH with AVP in the corresponding fields of view, with AVP immunopositive varicosities highlighted by arrows in
(B2,D2). (B3,C3,D3) Are overlays of (B,C,D1,D2) showing the lack of colocalization of AVP signal with that of the corresponding neuropeptides. Scale bars 10 µm.
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FIGURE 9 | Acute stress engages the AVP-V1a-b system in the LC. (A1) Shows TH immunoreactivity in the LC from a control mouse. (A2) Shows, in the same field
of view, immunoreactivity for the V1a receptor. (A3) Is an overlay of (A1,A2). (A4) Shows TH immunoreactivity in the LC from tissue of a mouse exposed to 1 h of
restraint stress and killed an hour later, processed and imaged under conditions identical to control subjects. (A5) Shows, in the same field of view, immunoreactivity
for V1a, with no discernible difference in labeling pattern and intensity evident between stress and control samples. (A6) Is an overlay of (A4,A5). (B1) Shows TH
immunoreactivity in the LC from a control mouse. (B2) Shows, in the same field of view, immunoreactivity for the V1b receptor. (B3) Is an overlay of (B1,B2). (B4)
Shows TH immunoreactivity in the LC from tissue of a mouse exposed to 1 h of restraint stress. (B5) Shows, the same field of view, immunoreactivity for V1b.
A dramatic stress-induced increase in the intensity of V1b signal is noticeable, both on cell surfaces but also in cytoplasmic components, suggesting a
stress-induced internalization, presumably via prolonged activation. (B6) Is an overlay of (B4,B5), which exemplifies the differences between the immunoreactivity
patterns in control and stress samples. (C1) Shows TH immunoreactivity in the LC from a control mouse. (C2) Shows, the same field of view, immunoreactivity for
AVP. (C3) Is an overlay of (C1,C2) with TH and AVP pseudo-colored blue and yellow respectively. (C4) Shows TH immunoreactivity in the LC from tissue of a mouse
exposed to 1 h of restraint stress and killed an hour later, processed and imaged under conditions to identical control subjects. (C5) Shows, the same field of view,
immunoreactivity for AVP. A stress-induced decrease in the intensity of AVP signal is noticeable as well as the relative lack of immunoreactive varicosities. This is
exemplified in (C6), when compared to (C3). Scale bars (A,B) 10 µm; (C) 100 µm.
One of the most intriguing findings of the study is that V1a-
b receptor ligands had contrasting effects on the spontaneous
firing activity of LC neurons. Post hoc neurochemical analyses
confirmed that all recorded neurons were located within the
LC and were noradrenergic. There could be a number of
reasons why, presumably, the activation of a single receptor
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type, on a specific cell type, induces contrasting effects on
cellular excitability. Firstly, contrasting downstream receptor
signaling cascades could be induced in different populations
of LC noradrenergic neurons, following their activation. As
receptors coupled to G protein (GPCRs), V1a and V1b
receptors conventionally couple to the Gq and phospholipase
C (PLC) pathway with the V2 receptor engaging the Gs and
adenylate cyclase (Gs-cAMP) pathway (Koshimizu et al., 2012).
However, individual AVP receptors engaging differing secondary
messenger cascades is not unprecedented. Indeed, multiple
mechanisms have been identified which result in the differential
activation of secondary messenger pathways by individual
GPCRs. These include receptors adopting different active and
inactive conformational states when bound to ligands (Kenakin,
2003), having the ability to homo- or heterodimerise, leading
to variations in their pharmacological properties (Park and
Palczewski, 2005) and the location of receptors within specialized
microdomains of the plasma membrane such as rafts or caveolae
(Guzzi et al., 2002). Such versatility in signal transduction has
been exemplified by the V1b receptor which has been shown
to activate either the IP or cAMP pathways (Jard et al., 1986;
Thibonnier et al., 1997; Sabatier et al., 1998). Furthermore, the
V1b receptor is capable of simultaneously activating both the
Gq/11-inositol phosphate (IP) and Gs-cAMP pathways (Orcel
et al., 2009). We are unable to distinguish from our data which
of the above variables could contribute to the differences in the
effects of desmopressin on the recorded neurons. A fundamental
question is whether the directionality of the AVP response
depends on the activity or metabolic state of the neuron, or it
is a central feature of specific sub-populations of LC neurons. If
the former, this could identify a role for AVP driving LC activity
toward basal levels following various triggers which elevate
excitability, such as stress (discussed below), or those which
decrease LC activity, such the release of opioids, thus in keeping
with its universal role of a homeostatic regulator. If the latter
applies, this could be a mechanism for magnifying the diversity
of LC noradrenergic neuron sub-populations. Indeed, the LC has
been shown to be composed of genetically diverse noradrenergic
neurons which are considered to represent different cell types
(Robertson et al., 2013; Plummer et al., 2017). Future high
resolution molecular, physiological and behavioral correlative
studies are required to address these questions. Irrespective, and
given the correlation between LC FR and NA release, these data
identify the AVP-V1a-b receptor system as possibly being capable
of both enhancing or diminishing NA release within the brain.
Precisely how AVP receptors change the spontaneous FR of
LC neurons is unclear. This could be an indirect response to the
modulation of local neurotransmitters, given the close association
of these receptors with GABA and glutamate synaptic molecular
machinery demonstrated in this study, and functional evidence
in other brain regions (Raggenbass, 2008; Rood and Beck, 2014).
Although we recorded from only noradrenergic neurons of the
LC, our immunohistochemical data confirm the presence of V1b
receptors in non-noradrenergic LC neurons. These neurons bear
the neurochemical hallmarks of inhibitory interneurons (Aston-
Jones et al., 2004; Corteen et al., 2011). If so, applied desmopressin
could induce the release of their neurotransmitter content
locally, thereby impacting on the excitability of the recorded
noradrenergic neuron. Paired recordings between identified
interneuron-principal cell pairs would be essential to understand
this dynamic of the AVP-LC system.
However, based on the changes in membrane properties
induced by desmopressin, AVP could also directly alter LC
neuronal excitability. In addition to changes in spontaneous
action potential frequency, desmopressin also altered the
membrane time constant for the AHP, thus impacting on the
time taken for the neuron to repolarise and thus be capable
of initiating the next action potential. This effect on the LC
inter-spike interval, by other neurohormones such as CRH,
has been shown to be modulated by potassium conductances
(Jedema and Grace, 2004). Furthermore, CRH, in different cell
types, has been shown to engage different secondary messenger
pathways (Grammatopoulos et al., 2001), resulting in either
the activation or inhibition of specific ion channels (Aldenhoff
et al., 1983; Rainnie et al., 1992; Yu and Shinnick-Gallagher,
1998). Finally, desmopressin also significantly altered the action
potential amplitude, but only in those cells which exhibited
a decreased FR. It is therefore reasonable to speculate that
AVP directly alters LC activity via the downstream modulation
of ion channels associated with spontaneous FR. However,
desmopressin did not alter the input resistance of the entire cell,
thus arguing against any potential impact on membrane channel
gating. Future studies investigating LC neuronal excitability in
AVP receptor subtype-specific knock out mice will hopefully
confirm the receptor subtype signaling cascaded in individual LC
neurons.
A novel discovery was the changes in the patterns of
AVP and V1b receptor immunoreactivity following exposure
to acute stress. Importantly, V1a receptor immunoreactivity
remained unchanged. An indicator of metabotropic receptor
activation is receptor internalization from plasma membranes
and incorporation within cytoplasmic compartments. Thus,
the dramatic stress-induced internalization of V1b localization
suggests engagement of stress signals with this receptor system
and a potential pathway mediating the LC stress response. Future
functional and behavioral studies are essential to identify the
underlying mechanisms. We deliberately chose an acute stress
protocol that is likely to engage adaptive or homeostatic pathways
throughout the body including the LC. This has been widely
demonstrated with the acute exposure to restraint stress used
in this study (Buynitsky and Mostofsky, 2009). LC neurons
are exquisitely sensitive to both emotional and physiological
stressors, responding with an increased FR (Valentino and Van
Bockstaele, 2008). The principal mediator of this stress-induced
LC excitability is CRH, originating from a variety of brain
centers (Valentino et al., 1992). Although AVP release from the
hypothalamus coincides with that of CRH and the stress response
(Kormos and Gaszner, 2013), its involvement in the LC stress
pathways has yet to be documented. However, this would not
be surprising, given the overlap of the LC, and AVP in general,
in mediating adaptive or homeostatic responses to various
psychological and physiological challenges (Valentino and Van
Bockstaele, 2008; Koshimizu et al., 2012). If so, this could signal
a novel partnership with CRH in regulating LC activity during
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times of stress. Precisely how these systems might cooperate is
unclear. An important distinction would be their contribution
to resting LC FR. CRH antagonists do not alter resting LC FR
thus indicating that this aspect of LC physiology is not mediated
by the CRH system. In contrast, this study demonstrated that
selective V1a-b receptor antagonists, on their own, significantly
altered basal LC FR, indicating that endogenous AVP sets the
tone of LC activity. Another difference would be the ability of
the AVP-V1a-b receptor system to bi-directionally modulate LC
activity. This distinguishes AVP-V1a-b system not only from the
CRH but other neuropeptide systems that influence LC activity
by either selectively increasing or decreasing activity, but never
both (Zitnik, 2016). It would be intriguing to explore whether
AVP would increase, or decrease, the activity of LC neurons,
in a behavioral or physiological state-dependent manner. CRH
is called upon during the stress response to elevate LC activity
and enhance NA release. However, central to an adaptive or
healthy stress system is the appropriate cessation of the stress
response once the organism has effectively contended with
the challenge. If AVP did work in tandem with CRH in this
process, it could provide a counter measure by reversing any
increase in LC activity, thereby ensuring effective resetting of
basal LC activity. This could provide unique opportunities for
V1a-b receptor ligands in psychiatric disorders associated with
an impaired stress response and LC dysregulation, such as
anxiety and depression (Itoi and Sugimoto, 2010). Indeed, in
humans, the dysregulation of brain and CSF AVP levels are
associated with a number of anxiety disorders (Neumann and
Landgraf, 2012). Furthermore, the pharmacological blockade
of either the V1a or V1b receptors showed anxiolytic and
antidepressant actions (Koshimizu et al., 2012; Caldwell et al.,
2017). The actions of these receptors on such emotional states
have been attributed to changes in the functions of a range
of brain regions such as the hypothalamus, the bed nucleus of
the stria terminallis and amygdala, with the LC largely ignored.
The current data suggest that the LC should be considered as
a site of action for such agents in altering such psychiatric
symptoms. The use of cell type-specific AVP receptor knock
out mice will be instrumental in dissecting the association of
specific brain regions and AVP receptor subtypes in these brain
functions.
In summary, the study provides a new vista on the central AVP
system, by providing the molecular and physiological constructs
of this neurohormone, and its associated receptor system, in the
mouse LC. The data will serve as the basis to further dissect the
contribution of what is conventionally a homeostatic system, to
the functioning of a brain region that is integral to mediating
adaptive responses to a variety of threats.
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